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SUMMARY
Fourteen patients in whom peritoneovenous shunts were inserted for intractable
ascites or malignancy were reviewed.
Reduction in ascites was obtained in all patients by the time of discharge with
significant diuresis and weight loss. Significant decrease in haemoglobin, packed
cell volume, platelet count and prothrombin time also occurred. Coagulation
studies were abnormal in 60 per cent ofpatients in whom they were performed
with bruising or detectable bleeding occurring in 28.5 per cent of all patients.
Late blockage of the shunt occurred in five patients and was less frequent in
Denver than in Le Veen type shunts.
Cumulative mortality one month after shunt insertion was 28.5 per cent and at
one year was 78.5 per cent reflecting the severity of the underlying disease.
Peritoneovenous shuntingshouldbe reservedforpalliation inpatients resistant to
full conventional medical therapy.
INTRODUCTION
In peritoneovenous shunting, ascitic fluid is returned to the venous circulation
using a device consisting of silicone tubing and a one-way valve. A short general
anaesthetic is required to insert one end of the shunt into the peritoneal cavity,
tunnel the shunt subcutaneously over the rib cage and insert the venous end into
the internal jugular vein. Peritoneovenous shunting is successful in the
management of resistant ascites in cases of portal hypertension or malignancy.
Several complications of the technique have, however, been reported.,
We present the limited experience of one unit with peritoneovenous shunting in
patients with medically resistant ascites. Medical therapy included bed rest, salt
restriction, water restriction and Frusemide and Spironolactone in doses up to
120 mg and 400 mg respectively daily.
PATIENTS
Fourteen consecutive patients in whom peritoneovenous shunts were inserted
were reviewed. There were 12 males and two females. The mean age was 55.2
years (range 23-78 years). Ascites was secondary to alcoholic cirrhosis in seven
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Fig 1. Diagram of Denver type of peritoneo-
venous shunt (With permission of Downs
Surgical Limited).
patients, to cryptogenic cirrhosis in four,
to malignancy in two (one primary
hepatocellular carcinoma and one
adenocarcinoma of the stomach) and a
further patient had severe Budd-Chiari
syndrome. Two of the patients with
alcoholic cirrhosis were subsequently
shown to have hepatocellular carcinoma
after insertion of the shunt. In the
cirrhotic group there were seven patients
in Child's grade C category and five in
Child's grade B.
Six LeVeen and eight Denver shunts
were inserted (Fig 1). Less than half a
litre of ascitic fluid was removed at the
time of inserting the shunt. Reduction
of ascites was assessed using girth
measurements, weight loss and urine
output. In eight patients Frusemide was
used to promote- diuresis postoper-
atively. In some patients the rate of flow
through the shunt was increased by
using the technique ofintermittent suck-
ing through a straw to increase the
negative intrathoracic pressure. Values
of sodium, potassium, urea, creatinine,
bilirubin, alanine transaminase, total
protein, albumin, haemoglobin, packed
cell volume, platelet count and prothrombin time before and after shunting were
compared using the Wilcoxan Signed Rank Test for non-parametric paired data.
RESULTS
All but one patient had lost weight by the
end of the first postoperative week; the
mean weight loss was 4.6 kilograms
(p < 0.01). Figure 2showsthe increased
mean urinary output on the third post-
operative day (p < 0.01) but by the end
of the first week this had tailed-off. The
haemoglobin values fell from 13.6 to
1 1.2 gm/dl (p< 0.05), and packed cell
volume from 0.396 to 0.339 (p< 0.01).
The platelet count fell postoperatively
from 187 x 103/L to 102 x 103/L
(p < 0.05). Prothrombin time decreased
in all 10 patients in whom it was
measured (mean values 54 to 30 per
cent (p < 0.01). No statistically signifi-
cant changes occurredinthe other blood
tests.
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Fig 2. The 24-hour urine output preopera.
tively and on the third postoperative day. The
changes were significant using the Wilcoxan
Signed Rank Test (p < 0.01).
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MORBIDITY
Abnormalitiesof coagulation werecommon aftershunt insertion. Full coagulation
studies were performed in 10 of the 14 patients and were abnormal in six.
Clinically detectable bleeding from the wound, gastrointestinal or genitourinary
systems was noted in four patients. Excessive bruising occurred in a further two
cases and one patient died on the third postoperative day from uncontrollable
disseminated intravascular coagulation.
Two patients developed ascitic leaks postoperatively and one of these subse-
quently developed staphylococcal septicaemia. Although this was initially
controlled by antibiotics, one month later further septicaemia and staphylococcal
ascitic infection proved fatal. Oneotherpatient diedofstaphylococcal septicaemia
20 days after insertion of the shunt. Two patients developed pulmonary oedema
to some degree on the first and second postoperative days respectively, and both
responded to conventional medical therapy. One patient bled from oesophageal
varices on the second postoperative day but this settled with conservative
management. Late blockage of the shunt occurred in five patients after an
average of 10 months (range one to 30 months). Ofthe six episodes of blockage,
four occurred at the abdominal catheter and only two at the venous catheter.
MORTALITY
Three patients died during the hospital admission in which the shunt was inserted.
One died on the third postoperative day from disseminated intravascular
coagulation, the other two from liver failure on the thirteenth and fourteenth
postoperative days respectively. Ofthe 1 1 patients who survived to leave hospital,
nine subsequently died after a mean survival of nine months (range three weeks
to 40 months). Death was due to liver failure in four patients and, in two of these,
hepatocellular carcinoma was documented prior to death. Other causes of
mortality were infected ascites in two, carcinoma in two and variceal haemorrhage
in one. The cumulative mortality was 28.5 per cent one month after operation;
42.8 per cent at two months; 57 per cent at six months and 78.6 per cent at one
year. Only two patients still survive, one five years, the other seven years after
insertion of their shunts.
DISCUSSION
The vast majority of patients with ascites of cirrhotic origin can be successfully
managed with low sodium intake, fluid restriction and diuretics. Diuretics,
however, contract the extracellular fluid compartment and this may induce renal
failure refractory to further therapy. Failure to respond to medical management
has been reported in 4.5 per cent of ascitic patients.2 Intermittent intravenous
reinfusion ofascitic fluid was seen to bring transient relief of ascites. In attempts to
produce sustained relief a variety of the neurosurgical pressure activated shunts
were tried.3 4 In 1974 LeVeen introduced a peritoneovenous shunt specifically
designed for management of resistant ascites.5 The Denver shunt modification
allows manual pumping of the valve.6 These devices allow the peritoneal cavity to
be drained through a one-way valve into a central vein. During inspiration the
intraperitoneal pressure rises while the intrathoracic pressure falls; pressure
differences of greater than four centimetres of water can then propel ascitic fluid
into the central vein.
Peritoneovenous shunting is effective in reducing ascites. The weight loss and
increased urine output in our patients cannot be attributed to the fluid volume
removed on inserting the shunt, or to paracentesis alone. Indeed the degree of
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weight loss and diuresis in our patients was similar to that reported in other
series.7 8 11 A fall in packed cell volume has been used as a measure of the
effective transfer of fluid into the venous circulation.8,9 Although a statistically
significant fall in packed cell volume occurred in our series, it was accompanied
by a concomitant fall in haemoglobin which may, in part, account for the change.
Bernhoft reported 84 per cent control of ascites at two months, 65 per cent at six
months and 50 per cent at one and two years, which is slightly better than our
findings.9 In the hepato-renal syndrome, however, the results appear more
variable. There are several reports of improvement1l 7, 10, 11 although, in some of
these, strict criteria for the syndrome may not have been applied.12 The absence
of statistically significant changes in total protein and albumin in our series is
surprising, for it is assumed that the transfer of protein into the vascular compart-
ment contributes to the reduction in ascites. Greenlee obtained similar results but
noted that significant changes in protein concentration occurred six months after
shunting.2
Coagulation abnormalities after shunt insertion are well recognised, the reported
incidence varying from 20 to 91 per cent.7-16 The incidence of coagulation
abnormalities and detectable bleeding in our series is comparable with the
observations of most authors.7 11,13,15 The triggering factor in the fluid has been
ascribed to endotoxin, thromboplastin and activated clotting factors. Schwartz14
and Ragni15 believe that coagulopathy is related to release into the systemic
circulation of ascitic fluid rich in fibrin degradation products. Treatment of the
coagulopathy has consisted of heparin, epsilon-amino-caproic acid and infusion
of blood products.7 Infusion of antithrombin III appears ineffective.16 Removal of
an amount of ascitic fluid at the time of operation may reduce the risk of dissem-
inated intravascular coagulation but results appear variable.1 8, 13 Spontaneous
resolution of the abnormal coagulation tends to occur towards the end of the first
postoperative week,14 but, in severe cases, ligation of the shunt has been
advocated to stop progression of the coagulopathy.7
Bleeding from oesophageal varices after shunting is related to expansion of the
blood volume with resultant increase in portal pressure, and removal of a large
amount of ascitic fluid at operation may reduce this possibility. LeVeen suggests
that shunting should be performed only after decompression of the portal
system.7 Leakage of ascitic fluid is a commonly recognised problem after
shunting.7-9 12 If the ascitic fluid becomes infected, mortality is high. Greenlee
found infection a major factor in his early postoperative deaths, stating that
preoperative ascitic fluid cell counts and culture should be performed to lessen
the risk of shunting infected ascites. Foreign bodies such as catheters or
intravenous cannulas should be removed early to minimise sources of potential
infection. The low incidence of blocked Denver shunts compared with LeVeen in
our survey confirms previous reports; 17, 19 it is related to the percutaneous
pumping chamber of the Denver shunt which allows dislodgement of fibrin clots.
Significant symptomatic relief of ascites was obtained in our patients, tallying with
the findings of other authors.1922 A major concern of shunting in malignant
disease is the systemic dissemination of tumour cells, but this is usually not
important in the short-term survival expected. Maat reported such a case23 and
Berger has noted subcutaneous tumour growth along the shunt.24 Unfortunately
blockage of the shunt is not uncommon in patients with malignant ascites.22 The
high cumulative mortality reflects the severity of the underlying disease process
in the patients who were considered for shunting. In liver disease, Child's grading
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correlates with survival after shunting, the poorest prognosis occurring in those
patients with functional renal failure.25 26,27
Our study confirms that peritoneovenous shunting is effective in treating intract-
able ascites. However, morbidity and mortality are such thatthe technique should
be reserved for cases resistant to full dose medical therapy.
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